Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and
immunological impact of cladribine tablets after treatment with natalizumab in patients with
relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple
sclerosis (active SPMS).